Details of Disease

General Information of Disease (ID: DISBM6EQ)

• Disease Name: Bronchitis
• Synonyms: recurrent wheezy bronchitis; chest infection; chest cold; acute bronchitis and bronchiolitis; chronic bronchitis; acute bronchitis; inflammation of bronchus; bronchus inflammation; bronchial infection; CI - chest infection
• Disease Class: CA20: Bronchitis
• Definition: An acute or chronic inflammatory process affecting the bronchi.
• Disease Hierarchy:
  DISWD40R: Disease
  DISCZT2B: Bronchial disorder
  DISSOPYR: Tracheobronchitis
  DISBM6EQ: Bronchitis
• ICD Code:
  ICD-11: ICD-11: CA20
  ICD-10: ICD-10: J40
  Expand ICD-11: 'CA20
  Expand ICD-10: 'J40
• Disease Identifiers:
  MONDO ID: MONDO_0003781
  MESH ID: D001991
  UMLS CUI: C0006277
  MedGen ID: 2736
  HPO ID: HP:0012387
  SNOMED CT ID: 32398004

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 31 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Acetylcysteine	DMWSXI4	Approved	Small molecular drug	[1]
Ambroxol	DMWJE9D	Approved	Small molecular drug	[2]
Aminophylline	DML2NIB	Approved	Small molecular drug	[3]
Amphotericin B	DMTAJQE	Approved	Small molecular drug	[4]
Bronchostat	DM0SJ4D	Approved	NA	[5]
Cefixime	DMY60I8	Approved	Small molecular drug	[6]
Cefprozil	DM7DSYP	Approved	Small molecular drug	[7]
Clofoctol	DMRJW8H	Approved	Small molecular drug	[5]
Cyclacillin	DMHSJB4	Approved	Small molecular drug	[8]
Cysteine Hydrochloride	DM5ONA9	Approved	Small molecular drug	[9]
Demeclocycline	DMZEPFJ	Approved	Small molecular drug	[5]
Dirithromycin	DM0D9YJ	Approved	Small molecular drug	[10]
Doxycycline	DM7ICNU	Approved	Small molecular drug	[11]
Ephedrine	DMMV0KW	Approved	Small molecular drug	[12]
Epinephrine	DM3KJBC	Approved	Small molecular drug	[13]
Erdosteine	DM6QFSV	Approved	Small molecular drug	[5]
Fudosteine	DMEGBNT	Approved	Small molecular drug	[5]
Fusidic Acid	DMWVCF3	Approved	Small molecular drug	[14]
Lomefloxacin	DMVRH9C	Approved	Small molecular drug	[15]
Minocycline	DMVN5OH	Approved	Small molecular drug	[16]
Miokamycin	DML1I4G	Approved	Small molecular drug	[5]
Norepinephrine	DMOUC09	Approved	Small molecular drug	[17]
Norfloxacin	DMIZ6W2	Approved	Small molecular drug	[18]
Ofloxacin	DM0VQN3	Approved	Small molecular drug	[19]
Oxytetracycline	DMOVH1M	Approved	Small molecular drug	[20]
Pirbuterol	DMI5678	Approved	Small molecular drug	[21]
Plazomicin	DMKMBES	Approved	Small molecular drug	[22]
Stepronin	DMG1NCU	Approved	Small molecular drug	[5]
Terbutaline	DMD4381	Approved	Small molecular drug	[23]
Tetracycline	DMZA017	Approved	Small molecular drug	[24]
Theophylline	DMRJFN9	Approved	Small molecular drug	[25]

This Disease is Treated as An Indication in 3 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AG-NPP709	DM96ZMU	Phase 3	NA	[26]
OP-145	DMQLXKK	Phase 2	Peptide	[28]
L-cysteine	DMCMOS8	Clinical trial	Small molecular drug	[29]

This Disease is Treated as An Indication in 1 Drugs in Phase 3 Trial

Drug Name	Drug ID	Highest Status	Drug Type	REF
Azithromycin	DMS6UOE	Phase 3 Trial	Small molecular drug	[27]

This Disease is Treated as An Indication in 2 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Cilomilast	DMHSM7I	Discontinued in Phase 3	Small molecular drug	[30]
NE-1530	DMCF8RQ	Discontinued in Phase 1	Small molecular drug	[31]

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ZP-010	DM19ZDQ	Investigative	NA	[32]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 4 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
HDAC2	TTSHTOI	moderate	Therapeutic	[33]
HDAC11	TT8K17W	Strong	Genetic Variation	[34]
PLOD1	TTEKJP3	Strong	Biomarker	[35]
TNFRSF18	TTG6LA7	Strong	Biomarker	[36]

This Disease Is Related to 6 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
FOXJ1	OT7LLBZ7	Strong	Altered Expression	[37]
GYPB	OTESHUIX	Strong	Genetic Variation	[38]
GYPE	OTBHAG6A	Strong	Genetic Variation	[38]
RAB5A	OTFR2KM4	Strong	Posttranslational Modification	[39]
SARS1	OTFKXQ1O	Strong	Biomarker	[40]
SPECC1	OTPEML48	Strong	Biomarker	[41]

References

• [1] Acetylcysteine FDA Label
• [2] The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice. Brain Dev. 2013 Apr;35(4):317-22.
• [3] Aminophylline FDA Label
• [4] Amphotericin B FDA Label
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [6] Cefixime FDA Label
• [7] Cefprozil FDA Label
• [8] Cyclacillin FDA Label
• [9] Cysteine Hydrochloride FDA Label
• [10] Dirithromycin FDA Label
• [11] Doxycycline FDA Label
• [12] Ephedrine FDA Label
• [13] Epinephrine FDA Label
• [14] [Interferon-gamma receptor 1 deficiency in a 19-month-old child: case report and literature review]. Zhonghua Er Ke Za Zhi. 2014 May;52(5):387-91.
• [15] Lomefloxacin FDA Label
• [16] Minocycline FDA Label
• [17] Norepinephrine FDA Label
• [18] Norfloxacin FDA Label
• [19] Ofloxacin FDA Label
• [20] Oxytetracycline FDA Label
• [21] Pirbuterol FDA Label
• [22] In vitro activity of plazomicin against -lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE).J Antimicrob Chemother. 2017 Oct 1;72(10):2792-2795.
• [23] Terbutaline FDA Label
• [24] Tetracycline FDA Label
• [25] Theophylline FDA Label
• [26] ClinicalTrials.gov (NCT01151202) Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "AG NPP709 Syrup". U.S. National Institutes of Health.
• [27] FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 065511.
• [28] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020797)
• [29] Oxidation pathway and exacerbations in COPD: the role of NAC. Expert Rev Respir Med. 2016;10(1):89-97.
• [30] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7407).
• [31] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002903)
• [32] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [33] Low-dose theophylline restores corticosteroid responsiveness in rats with smoke-induced airway inflammation.Can J Physiol Pharmacol. 2012 Jul;90(7):895-902. doi: 10.1139/y2012-079. Epub 2012 Jun 18.
• [34] Mitochondrial bioenergy alterations in avian HD11 macrophages infected with infectious bronchitis virus.Arch Virol. 2018 Apr;163(4):1043-1049. doi: 10.1007/s00705-018-3704-2. Epub 2018 Jan 4.
• [35] Sibs affected with both Ehlers-Danlos syndrome type IV and cystic fibrosis.Am J Med Genet. 1998 Aug 6;78(5):455-60. doi: 10.1002/(sici)1096-8628(19980806)78:5<455::aid-ajmg11>3.0.co;2-e.
• [36] miR-146a-5p promotes replication of infectious bronchitis virus by targeting IRAK2 and TNFRSF18.Microb Pathog. 2018 Jul;120:32-36. doi: 10.1016/j.micpath.2018.04.046. Epub 2018 Apr 24.
• [37] Effects of paramyxoviral infection on airway epithelial cell Foxj1 expression, ciliogenesis, and mucociliary function.Am J Pathol. 2001 Dec;159(6):2055-69. doi: 10.1016/S0002-9440(10)63057-X.
• [38] Exposure to cold and draught, alcohol consumption, and the NS-phenotype are associated with chronic bronchitis: an epidemiological investigation of 3387 men aged 53-75 years: the Copenhagen Male Study.Occup Environ Med. 2001 Mar;58(3):160-4. doi: 10.1136/oem.58.3.160.
• [39] Infectious bronchitis virus entry mainly depends on clathrin mediated endocytosis and requires classical endosomal/lysosomal system.Virology. 2019 Feb;528:118-136. doi: 10.1016/j.virol.2018.12.012. Epub 2018 Dec 28.
• [40] Two-way antigenic cross-reactivity between severe acute respiratory syndrome coronavirus (SARS-CoV) and group 1 animal CoVs is mediated through an antigenic site in the N-terminal region of the SARS-CoV nucleoprotein.J Virol. 2007 Dec;81(24):13365-77. doi: 10.1128/JVI.01169-07. Epub 2007 Oct 3.
• [41] Development and application of nsp5-ELISA for the detection of antibody to infectious bronchitis virus.J Virol Methods. 2017 May;243:182-189. doi: 10.1016/j.jviromet.2017.01.026. Epub 2017 Feb 20.